WuXi Biologics has started building its antibody-drug conjugate (ADC) centre in Wuxi City, China, where it will offer biologics conjugate services for clients.
With $12m in Series C financing, AbSci is looking to tackle the antibody market by accelerating innovation and driving down manufacturing costs using its synthetic biology platform, says CEO.
Cellectis has built a switch into a chimeric antigen receptor (CAR) T-cell to provide an efficient way to eliminate the therapy if it becomes a threat to patient safety.
The Republic of Ireland’s competitive corporate tax rate represents a ‘stability’ that may not be found in other economies, says IDA Ireland executive.
The US FDA has approved Merck & Co.’s bestseller Keytruda for two additional oncology indications – cervical cancer, and relapsed primary mediastinal large B-cell lymphoma.
Eisai says it is creating a research facility for ‘genetics-guided dementia discovery’ in the US and joining a Japanese industry-academia-government collaboration aimed at developing nucleic acid-based drugs.
Many unanswered questions surrounding the nascent biosimilar market are creating challenges – though less regulated markets may benefit from 'less well defined' definitions, says analyst.
Parker Bioscience outlines its planned investment to meet demand as the industry shifts from traditional processes to biological – for which single-use products are critical, says exec.
WuXi Biologics has announced plans to build a $60m manufacturing facility – offering continuous manufacturing options – for clinical and commercial production in the US.
GE Healthcare has announced plans to install its second FlexFactory manufacturing platform for cell therapy, this time at Xiangxue Pharmaceutical’s site in Guangzhou, China.
